Do analysts recommend VRAX or VERO?

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 1,685.71%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, VRAX or VERO?

Virax Biolabs Group has higher earnings, but lower revenue than Venus Concept. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 112.00 -$5.02M N/A N/A Venus Concept $58.88M 0.01 -$47M -$48.84 N/A

Do analysts recommend VERO or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BTCY or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BTCY or VERO more profitable?

Biotricity has a net margin of -80.42% compared to Venus Concept's net margin of -92.76%. Biotricity's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Biotricity -80.42% N/A -188.47% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts prefer PFSA or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PFSA or VERO?

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa $100K 5.49 -$35.82M -$5.62 thousand N/A Venus Concept $58.88M 0.01 -$47M -$48.84 N/A

Is PFSA or VERO more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,731.09% Venus Concept -92.76% -1,904.25% -85.22%

Does the media refer more to PFSA or VERO?

In the previous week, Profusa and Profusa both had 1 articles in the media. Profusa's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Venus Concept 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GCTK or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GCTK or VERO more profitable?

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% Venus Concept -92.76% -1,904.25% -85.22%

Does the media favor GCTK or VERO?

In the previous week, GlucoTrack and GlucoTrack both had 1 articles in the media. GlucoTrack's average media sentiment score of 0.99 beat Venus Concept's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Venus Concept 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 10/16/2026

Compare

VERO vs. VRAX, BBLG, BTCY, PFSA, and GCTK

Should you buy Venus Concept stock or one of its competitors? Venus Concept's main competitors and comparable companies include Virax Biolabs Group (VRAX), Bone Biologics (BBLG), Biotricity (BTCY), Profusa (PFSA), and GlucoTrack (GCTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Venus Concept compare to Virax Biolabs Group?

Virax Biolabs Group (NASDAQ:VRAX) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Virax Biolabs Group presently has a consensus price target of $25.00, suggesting a potential upside of 1,685.71%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, research analysts plainly believe Virax Biolabs Group is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has higher earnings, but lower revenue than Venus Concept.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	112.00	-$5.02M	N/A	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Venus Concept had 1 more articles in the media than Virax Biolabs Group. MarketBeat recorded 1 mentions for Venus Concept and 0 mentions for Virax Biolabs Group. Virax Biolabs Group's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Venus Concept	Neutral

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Virax Biolabs Group has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Virax Biolabs Group has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Virax Biolabs Group's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Virax Biolabs Group beats Venus Concept on 10 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Bone Biologics?

Venus Concept (NASDAQ:VERO) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Bone Biologics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bone Biologics' return on equity of -57.87% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Bone Biologics	N/A	-57.87%	-53.65%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Venus Concept had 1 more articles in the media than Bone Biologics. MarketBeat recorded 1 mentions for Venus Concept and 0 mentions for Bone Biologics. Venus Concept's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Bone Biologics	Neutral

Bone Biologics has lower revenue, but higher earnings than Venus Concept. Bone Biologics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 5.0% of Bone Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Summary

Bone Biologics beats Venus Concept on 6 of the 10 factors compared between the two stocks.

How does Venus Concept compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biotricity has a net margin of -80.42% compared to Venus Concept's net margin of -92.76%. Biotricity's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Venus Concept	-92.76%	-1,904.25%	-85.22%

3.9% of Biotricity shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 1.6% of Biotricity shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biotricity has higher earnings, but lower revenue than Venus Concept. Biotricity is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.08	-$14.09M	-$0.14	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Venus Concept had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Venus Concept and 0 mentions for Biotricity. Biotricity's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Venus Concept	Neutral

Biotricity has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Summary

Venus Concept beats Biotricity on 7 of the 13 factors compared between the two stocks.

How does Venus Concept compare to Profusa?

Profusa (NASDAQ:PFSA) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Profusa has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

9.8% of Profusa shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 15.0% of Profusa shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,731.09%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	$100K	5.49	-$35.82M	-$5.62 thousand	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, Profusa and Profusa both had 1 articles in the media. Profusa's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Venus Concept	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Profusa and Venus Concept tied by winning 5 of the 10 factors compared between the two stocks.

How does Venus Concept compare to GlucoTrack?

GlucoTrack (NASDAQ:GCTK) and Venus Concept (NASDAQ:VERO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 5.9% of GlucoTrack shares are held by insiders. Comparatively, 28.0% of Venus Concept shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, GlucoTrack and GlucoTrack both had 1 articles in the media. GlucoTrack's average media sentiment score of 0.99 beat Venus Concept's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Venus Concept	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Venus Concept's return on equity of -1,904.25% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Venus Concept	-92.76%	-1,904.25%	-85.22%

GlucoTrack has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Summary

Venus Concept beats GlucoTrack on 6 of the 11 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$442K	$5.73B	$7.43B	$12.65B
Dividend Yield	N/A	1.73%	2.50%	32.09%
P/E Ratio	-0.01	20.35	195.83	18.60
Price / Sales	0.01	66.00	580.05	78.09
Price / Cash	N/A	32.16	26.72	33.54
Price / Book	0.07	5.76	10.51	5.91
Net Income	-$47M	$146.70M	$3.50B	$380.61M
7 Day Performance	N/A	-1.77%	-2.23%	-3.39%
1 Month Performance	N/A	-5.17%	-9.05%	-8.25%
1 Year Performance	-86.50%	1.73%	-0.43%	-7.07%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.0615 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
VRAX Virax Biolabs Group	2.6618 of 5 stars	$1.76 +1.3%	$25.00 +1,320.5%	-90.8%	$1.41M	$10K	N/A	26
BBLG Bone Biologics	0.5474 of 5 stars	$0.41 -4.4%	N/A	-83.4%	$1.13M	N/A	N/A	2	Positive News Gap Down
BTCY Biotricity	N/A	$0.06 +23.0%	N/A	-92.2%	$1.10M	$12.06M	N/A	46	Gap Up
PFSA Profusa	0.4829 of 5 stars	$1.28 -0.4%	N/A	N/A	$778K	$100K	N/A	2	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 10/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. VRAX, BBLG, BTCY, PFSA, and GCTK

How does Venus Concept compare to Virax Biolabs Group?

Summary

How does Venus Concept compare to Bone Biologics?

Summary

How does Venus Concept compare to Biotricity?

Summary

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to GlucoTrack?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. VRAX, BBLG, BTCY, PFSA, and GCTK

How does Venus Concept compare to Virax Biolabs Group?

Do analysts recommend VRAX or VERO?

Which has stronger valuation & earnings, VRAX or VERO?

Does the media favor VRAX or VERO?

Do institutionals and insiders have more ownership in VRAX or VERO?

Which has more risk and volatility, VRAX or VERO?

Is VRAX or VERO more profitable?

Summary

How does Venus Concept compare to Bone Biologics?

Is VERO or BBLG more profitable?

Do analysts recommend VERO or BBLG?

Does the media favor VERO or BBLG?

Which has higher valuation & earnings, VERO or BBLG?

Do insiders and institutionals have more ownership in VERO or BBLG?

Which has more volatility and risk, VERO or BBLG?

Summary

How does Venus Concept compare to Biotricity?

Do analysts rate BTCY or VERO?

Is BTCY or VERO more profitable?

Do insiders & institutionals hold more shares of BTCY or VERO?

Which has higher valuation and earnings, BTCY or VERO?

Does the media refer more to BTCY or VERO?

Which has more volatility and risk, BTCY or VERO?

Summary

How does Venus Concept compare to Profusa?

Which has more volatility and risk, PFSA or VERO?

Do institutionals & insiders hold more shares of PFSA or VERO?

Is PFSA or VERO more profitable?

Do analysts prefer PFSA or VERO?

Which has stronger earnings & valuation, PFSA or VERO?

Does the media refer more to PFSA or VERO?

Summary

How does Venus Concept compare to GlucoTrack?

Do insiders and institutionals believe in GCTK or VERO?

Do analysts rate GCTK or VERO?

Which has preferable earnings & valuation, GCTK or VERO?

Does the media favor GCTK or VERO?

Is GCTK or VERO more profitable?

Which has more volatility & risk, GCTK or VERO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools